Several clinical trials assessed the combination of immunotherapy targeting CTLA4 or PD-L1 with chemotherapeutic drugs as front-line treatment for pancreatic ductal adenocarcinoma. This evidence concerns the gene CTLA4 and pancreatic ductal adenocarcinoma.